From the Hemorrhagic Stroke Research Program, Department of Neurology (A.C., M.P., A.B., M.E.G., J.N.G., J.R., S.M.G., A.V.), Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; Alzheimer Center and the Neuroscience Campus Amsterdam and Departments of Radiology and Nuclear Medicine (H.I.Z., F.B.), VU University Medical Center, the Netherlands; Karolinska Institutet (S.S., L.-O.W.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (K.K., J.R.C.), Mayo Clinic, Rochester, MN; Department of Medicine (Neurology) (A.S.), McMaster University and Population Health Research Institute, Hamilton, Canada; Memory, Aging and Cognition Center (S.H., Y.L.C., J.R.C., C.C.), National University Health System, Singapore; Department of Pharmacology (S.H., Y.L.C., J.R.C., C.C.), National University of Singapore; Department of Nuclear Medicine and Centre for PET (P.A.Y.), The University of Melbourne, Parkville, Australia; Department of Neuroradiology (G.B.), Université Paris-Descartes, INSERM U894, CH Sainte-Anne, Paris, France; Department of Neurology and Neuroscience Center (H.K.N., D.L.N., S.W.S.), Samsung Medical Center, Seoul, Republic of Korea; UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK; and Center for Genomic Medicine (J.R.) and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston.
Neurology. 2019 Jul 23;93(4):e358-e371. doi: 10.1212/WNL.0000000000007818. Epub 2019 Jun 26.
To assess potential mechanisms of cortical superficial siderosis (cSS), a central MRI biomarker in cerebral amyloid angiopathy (CAA), we performed a collaborative meta-analysis of associations with cSS presence and severity.
We pooled data from published studies reporting genotype and MRI assessment of cSS in 3 distinct settings: (1) stroke clinic patients with symptomatic CAA (i.e., lobar intracerebral hemorrhage, transient focal neurologic episodes) according to the Boston criteria; (2) memory clinic patients; and (3) population-based studies. We compared cSS presence and severity (focal or disseminated vs no cSS) in participants with ε2+ or ε4+ genotype vs the ε3/ε3 genotype, by calculating study-specific and random effects pooled, unadjusted odds ratios (ORs).
Thirteen studies fulfilled inclusion criteria: 7 memory clinic cohorts (n = 2,587), 5 symptomatic CAA cohorts (n = 402), and 1 population-based study (n = 1,379). There was no significant overall association between ε4+ and cSS presence or severity. When stratified by clinical setting, ε4+ was associated with cSS in memory clinic (OR 2.10; 95% confidence interval [CI] 1.11-3.99) but not symptomatic CAA patients. The pooled OR showed significantly increased odds of having cSS for ε2+ genotypes (OR 2.42, 95% CI 1.48-3.95) in both patient populations. This association was stronger for disseminated cSS in symptomatic CAA cohorts. In detailed subgroup analyses, ε2/ε2 and ε2/ε4 genotypes were most consistently and strongly associated with cSS presence and severity.
CAA-related vasculopathic changes and fragility associated with ε2+ allele might have a biologically meaningful role in the pathophysiology and severity of cSS.
评估皮质浅层铁沉积(cSS)的潜在机制,cSS 是脑淀粉样血管病(CAA)的中枢 MRI 生物标志物,我们对与 cSS 存在和严重程度相关的因素进行了合作荟萃分析。
我们汇总了在 3 个不同环境中发表的研究数据,这些研究报告了 cSS 存在和严重程度的基因型和 MRI 评估:(1)根据波士顿标准,有症状 CAA(即,皮质下脑叶出血,短暂局灶性神经事件)的中风诊所患者;(2)记忆诊所患者;和(3)基于人群的研究。我们通过计算特定研究和随机效应汇总的未调整比值比(OR),比较 ε2+或 ε4+基因型与 ε3/ε3 基因型的 cSS 存在和严重程度(局灶性或弥散性与无 cSS)。
13 项研究符合纳入标准:7 项记忆诊所队列(n=2587),5 项有症状 CAA 队列(n=402)和 1 项基于人群的研究(n=1379)。 ε4+与 cSS 的存在或严重程度之间没有显著的总体关联。按临床环境分层, ε4+与记忆诊所患者的 cSS 相关(OR 2.10;95%置信区间[CI] 1.11-3.99),但与有症状 CAA 患者无关。汇总 OR 显示,在这两种患者人群中, ε2+基因型发生 cSS 的几率显著增加(OR 2.42,95% CI 1.48-3.95)。在有症状 CAA 队列中,弥散性 cSS 的相关性更强。在详细的亚组分析中, ε2/ε2 和 ε2/ε4 基因型与 cSS 的存在和严重程度最一致且最密切相关。
与 ε2+等位基因相关的 CAA 相关血管病变和脆弱性可能在 cSS 的病理生理学和严重程度中具有生物学意义。